How to buy Marker Therapeutics stock (MRKR)

Marker Therapeutics is a biotechnology business based in the US. Marker Therapeutics shares (MRKR) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.49 – a decrease of 8.16% over the previous week. Marker Therapeutics employs 8 staff and has a trailing 12-month revenue of around $3.7 million.

Our top picks for where to buy Marker Therapeutics stock

Buy Marker Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Marker Therapeutics stock price (NASDAQ: MRKR)

Use our graph to track the performance of MRKR stocks over time.

Marker Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-25.

Latest market close	$3.49
52-week range	$2.44 - $6.16
50-day moving average more info button	$3.72
200-day moving average more info button	$3.96
Wall St. target price	$19.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.07

Is it a good time to buy Marker Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Marker Therapeutics price performance over time

Historical closes compared with the close of $3.37 from 2024-12-26

1 week (2024-12-20)	-11.32%
1 month (2024-11-27)	5.64%
3 months (2024-09-27)	16.21%
6 months (2024-06-27)	-30.23%

1 year (2023-12-27)	-20.52%
2 years (2022-12-27)	29.62%
3 years (2021-12-27)	9.558
5 years (2019-12-27)	30.7

Marker Therapeutics financials

Revenue TTM	$3.7 million
Gross profit TTM	$-17,125,779
Return on assets TTM	-40.87%
Return on equity TTM	-71.74%
Profit margin	-278.22%
Book value	$1.58
Market Capitalization more info button	$36.2 million

TTM: trailing 12 months

Marker Therapeutics share dividends

We're not expecting Marker Therapeutics to pay a dividend over the next 12 months.

Have Marker Therapeutics's shares ever split?

Marker Therapeutics's shares were split on a 1:10 basis on 26 January 2023 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Marker Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Marker Therapeutics shares which in turn could have impacted Marker Therapeutics's share price.

Marker Therapeutics share price volatility

Over the last 12 months, Marker Therapeutics's shares have ranged in value from as little as $2.4377 up to $6.1568. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Marker Therapeutics's is 1.492. This would suggest that Marker Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Marker Therapeutics overview

Marker Therapeutics, Inc. , a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas. .

Frequently asked questions

What percentage of Marker Therapeutics is owned by insiders or institutions?
Currently 12.199% of Marker Therapeutics shares are held by insiders and 22.44% by institutions. How many people work for Marker Therapeutics?
Latest data suggests 8 work at Marker Therapeutics. When does the fiscal year end for Marker Therapeutics?
Marker Therapeutics's fiscal year ends in December. Where is Marker Therapeutics based?
Marker Therapeutics's address is: 9350 Kirby Drive, Houston, TX, United States, 77054 What is Marker Therapeutics's ISIN number?
Marker Therapeutics's international securities identification number is: US57055L1070 What is Marker Therapeutics's CUSIP number?
Marker Therapeutics's Committee on Uniform Securities Identification Procedures number is: 876033200